Reach Us +441704335730
Imidazo[2,1b ] Thiazole: Introduction, Current and Perspective | OMICS International
ISSN: 2167-7662
Bioenergetics: Open Access
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Imidazo[2,1b ] Thiazole: Introduction, Current and Perspective

Alberto Leoni*, Alessandra Locatelli, Rita Morigi and Mirella Rambaldi

Department of Pharmacy and Biotechnology, University of Bologna, Via Belmeloro 6, Bologna, Italy

*Corresponding Author:
Leoni A
Department of Pharmacy and Biotechnology, University of Bologna
Via Belmeloro 6, Bologna-40126, Italy
E-mail: [email protected]

Received date: March 15, 2017; Accepted date: April 18, 2017; Published date: April 24, 2017

Citation: Leoni A, Locatelli A, Morigi R, Rambaldi M (2017) Imidazo[2,1-b] Thiazole: Introduction, Current and Perspective. Bioenergetics 6:151. doi: 10.4172/2167-7662.1000151

Copyright: © 2017 Leoni A et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Bioenergetics: Open Access


Imidazo[2,1-b]thiazole (1) is a fused heterobicyclic system containing bridgehead nitrogen atom. Derivatives of this scaffold are especially attractive in the field of medicinal chemistry because of their broad spectrum of biological activities. The imidazo[2,1-b]thiazole system constitutes the core unit of the well-known anthelminthic and immunomodulatory agent Levamisole (2) (Figure 1), marketed under the trade name Ergamisol© and discovered at Janssen Pharmaceutica in 1966 [1].


Figure 1: Imidazo[2,1-b]thiazole (1) and Levamisole (2) some derivatives (3-11).

During last decades our group synthetized some series of imidazo[2,1-b]thiazole derivatives active against various cancer cell lines (3-8). We discovered that, for some selected molecules, their ability to inhibit cellular proliferation was mediated by cell cycle arrest at the G2/M phase, accompanied by inhibition of ornithine decarboxylase (ODC), the limiting enzyme of polyamine synthesis, and followed by induction of apoptosis (4) [2,3]. We studied also the effect of the guanylhydrazone derivatives bearing the scaffold of imidazo[2,1-b]thiazole. We found an inhibitor of Complex III of the mitochondrial respiratory chain inducing apoptosis in the cell lines HT29 and HL60 (5) [4]. Varying the substitutions on the thiazole ring of the imidazothiazole skeleton we obtained some imidazothiazole guanylhydrazones that block the cell cycle progression with a marked reduction in the mitochondrial transmembrane potential ΔΨm and a decrease in the intracellular ATP content (6) [5]. In the same period, we reported new series of substituted 3-(5-imidazo[2,1-b] thiazolylmethylene)-2-indolinones as anticancer agents. Among these, some derivatives exhibit growth inhibition in submicromolar range. Mechanistic studies of the most active compounds revealed that the apoptosis in the HT-29 cells was accompanied by caspase activation and phosphatidylserine externalization and that the most potent compounds strongly reduced Akt(Ser473) phosphorylation. Further mechanistic studies in colon adenocarcinoma (HT-29) cell line revealed that imidazo[2,1-b]thiazolylmethylene-2-indolinones, in some cases, are capable of blocking cells in M phase without interfering with microtubule dynamics (7,8) [6,7]. Recently we focused our attention on the synthesis and functional in vitro assay in cardiac and smooth muscle (vascular and nonvascular) of a library of 4-imidazo[2,1-b] thiazole-1,4-dihydropyridines to define their calcium blocker nature and their selectivity on Cav1.2 and Cav1.3 isoforms (9,10) [8,9]. Taking into account that 1,4-dihydropyridines that block L-type Ca2+ channels are also effective potentiators of the cystic fibrosis transmembrane conductance regulator (CFTR) gating able to correct the defective activity CFTR mutants, we evaluated the ability of the previously and newly synthesized 4-imidazo[2,1-b]thiazoles-1,4-dihydropyridines without vascular activity and inotropic and/or chronotropic cardiac effects to enhance the activity of CFTR mutants (11) [10].

The versatility of imidazo[2,1-b]thiazole nucleus has attracted the attention of many other academic researchers and of pharmaceutical companies [11,12]. In the last decade the research in this field has generated patents with heterogeneous therapeutic applications: modulators of transcription for modulators of activity at 5-HT6 receptor 12, inhibitors of the EGFR kinase activity 13, endothelial nitric oxide synthase 14, inhibitors of murine double minute 2 15, sirtuin modulators 16, treatment of Duchenne muscular dystrophy 17, inhibitors of p53 MAK kinase 18, potential anticancer agents 19, nematicides 20 and modulators of the tumor necrosis factor activity 21 (Figure 2) [13-22].


Figure 2: patented imidazo[2,1-b]thiazole derivatives (12-21).

The framework of imidazo[2,1-b]thiazole allows various substitution patterns and generally, they are obtained by classical synthetic routes or more novel protocols based on multicomponent reactions [23]. In recent years, the design and synthesis of pharmacologically relevant heterocyclic molecules by combinatorial techniques have proven to be a promising strategy in the search for new pharmaceutical lead structures. Click chemistry is one of the powerful reactions for making carbon-heteroatom-carbon bonds in aqueous environment with a wide variety of chemical and biological applications in various fields and it is a newer approach to the synthesis of drug like molecules that can accelerate the drug discovery process by utilizing a few practical and reliable reactions. Furthermore new therapeutic approaches that are currently being developed to circumvent the effectiveness of the current arsenal of anticancer agents may definitely lead to discover novel drugs having low toxicity and resistance. For example the search for a putative anticancer drug could involve a multiple-target approach to overcome potential mechanism(s) of resistance caused in part by redundancy and robustness of biological pathways and to afford compounds able to modulate multiple aspects of pathologies [24,25]. All these considerations prompt to us to continue the research based on the imidazo[2,1-b]thiazole core as a tool to discover small molecules that could be lead compound for anticancer therapy.


Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Article Usage

  • Total views: 642
  • [From(publication date):
    December-2017 - Dec 12, 2018]
  • Breakdown by view type
  • HTML page views : 560
  • PDF downloads : 82

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri and Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry


[email protected]

1-702-714-7001Extn: 9042

© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7